Oncology exploration: charting cancer medicinal chemistry space

Drug Discovery Today
David G LloydTudor I Oprea

Abstract

Approaches for the experimental determination of protein-ligand molecular interactions are reliant on the quality of the compounds being tested. The application of large, randomly designed combinatorial libraries has given way to the creation of more-focused 'drug-like' libraries. Prior to synthesis, we wish to screen the potential compounds to remove undesired chemical moieties and to be within a required range of physiochemical properties. We have used a principal-component analysis (PCA) computational approach to analyze the 3D descriptor space of active and non-active (hit-like) cancer medicinal chemistry compounds. We define hit-like those molecules passing the unmodified OpenEye FILTER program. Our analysis indicates that these compounds occupy quite different regions in space. Cancer-active compounds exist in a much greater volume of space than generic hit-like space and most of them fail the commonly applied filters for orally bioavailable drugs. This is of great significance when designing orally bioavailable cancer target drugs.

References

Jul 14, 2000·Drug Discovery Today·A R Leach, M M Hann
Mar 29, 2001·Journal of Pharmacological and Toxicological Methods·C A Lipinski
Apr 13, 2001·Journal of Combinatorial Chemistry·T I Oprea, J Gottfries
Sep 20, 2001·Current Pharmaceutical Design·M F BrañaA Ramos
Mar 30, 2002·Advanced Drug Delivery Reviews·W Patrick Walters, Mark A Murcko
Aug 28, 2002·Biochemical Society Transactions·J Mestres
Jan 28, 2003·Drug Discovery Today·Paul D Lyne
Feb 7, 2003·Current Medicinal Chemistry·M J Meegan, D G Lloyd
Mar 6, 2003·Bioorganic & Medicinal Chemistry Letters·Anders BråtheBjørn Spilsberg
Apr 8, 2003·Current Medicinal Chemistry. Anti-cancer Agents·M Malet-MartinoR Martino
Jul 31, 2003·Pharmacology & Therapeutics·Annette K LarsenAndrzej Skladanowski
Oct 8, 2003·Current Pharmaceutical Design·John J McGuire
Oct 14, 2003·Drug Discovery Today·Miles CongreveHarren Jhoti
Feb 18, 2004·Combinatorial Chemistry & High Throughput Screening·G HarperD V S Green
Feb 26, 2004·Drug Discovery Today·Daniela Fattori
Mar 23, 2004·Current Medicinal Chemistry. Anti-cancer Agents·Paolo CozziAntonino Suarato
Apr 14, 2004·Current Pharmaceutical Design·Tingjun Hou, Xiaojie Xu
May 27, 2004·Expert Review of Anticancer Therapy·Francesco Piazza, Gianpietro Semenzato
Jun 9, 2004·Current Opinion in Chemical Biology·Mike M Hann, Tudor I Oprea
Sep 15, 2004·Drug Discovery Today·Brian Desany, Zemin Zhang
Oct 29, 2004·Journal of Medicinal Chemistry·David G LloydMary J Meegan
Dec 8, 2004·Combinatorial Chemistry & High Throughput Screening·Stephen J HaggartyStuart L Schreiber
Dec 8, 2004·Current Medicinal Chemistry. Anti-cancer Agents·J NarashimamurthyG Narahari Sastry
Jan 11, 2005·Current Medicinal Chemistry·R Martínez, L Chacón-García
Jan 11, 2005·Current Pharmaceutical Design·Eric X Chen, Lillian L Siu
Jan 15, 2005·Annals of the New York Academy of Sciences·Giuseppe SaglioDaniela Cilloni
Feb 12, 2005·Science·Chetana M RevankarEric R Prossnitz
Mar 15, 2005·FEBS Letters·Silvia BenvenutiAlberto Bardelli
Apr 7, 2005·Current Cancer Drug Targets·Chung Fai WongAndrew J Burgess
May 10, 2005·Journal of Combinatorial Chemistry·Gang ChenHualiang Jiang
Jun 9, 2005·The Journal of Steroid Biochemistry and Molecular Biology·James N Ingle, Vera J Suman
Jun 23, 2005·Drug Discovery Today·Michal ViethRobert M Campbell
Jun 25, 2005·Current Medicinal Chemistry·Stephen J ShuttleworthAlex J Zhang
Jul 9, 2005·Expert Review of Anticancer Therapy·Constantine S MitsiadesKenneth C Anderson
Feb 14, 2006·Current Drug Discovery Technologies·Marius M OlahTudor I Oprea

❮ Previous
Next ❯

Citations

Mar 29, 2011·Journal of Chemical Information and Modeling·Haoliang YuanYadong Chen
Jul 19, 2011·Journal of Chemical Information and Modeling·Vincent Le GuillouxLuc Morin-Allory
May 15, 2013·Journal of Asian Natural Products Research·J Ujwal KumarA S Sreedhar
Oct 4, 2011·PloS One·Malgorzata N DrwalRenate Griffith
Jan 24, 2016·Drug Discovery Today·Serge MignaniJean-Pierre Majoral
Aug 1, 2008·Expert Opinion on Drug Discovery·Andrew Js KnoxMary J Meegan
Jun 22, 2010·Bioorganic & Medicinal Chemistry·Gaopeng SongYingxia Li
Jun 6, 2007·British Journal of Pharmacology·S EkinsB Testa
Jan 24, 2015·Journal of Biomolecular Screening·Julie K StockChristian Dillon
Nov 14, 2015·Journal of Computer-aided Molecular Design·Pavel SidorovDragos Horvath
Aug 14, 2008·Journal of Medicinal Chemistry·Maria Laura BolognesiCarlo Melchiorre
Jan 26, 2011·ACS Chemical Biology·David J HugginsDavid R Spring

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.